Instructional BiologyA protein's function isn't stored in its amino acids the way information is stored in letters on a page. It's stored in the precise three-dimensional shape those amino acids fold into — the alpha-helices, beta-sheets, and higher-order structures that let a molecule dock into a receptor the way a key fits a lock. Unfold that shape, even without breaking a single chemical bond, and the molecule can still be chemically present while being functionally silent. The amino acids are all there. The instruction they used to carry is gone.
This distinction matters more than it might seem, because it's exactly the gap between two things that sound similar but aren't: nutritional biology and instructional biology. Delivering amino acids to a cell supplies raw material. It doesn't supply the folded, three-dimensional signal that tells the cell what to do with that material. A pile of bricks isn't a house, no matter how structurally sound each individual brick is.
Why legacy processing destroys the signal
Biopharmaceutical manufacturing has historically prioritized one variable above all others: pathogen safety. That's a reasonable priority when working with tissue of uncertain origin, and it typically means high-heat sterilization — autoclaving well above 100°C. That level of heat reliably kills pathogens. It also reliably unfolds the larger, more structurally complex peptides in the material, at temperatures far below what's needed for sterilization itself.
The practical result is a category error the industry doesn't always name explicitly: a "sterilized" extract and a "biologically active" extract are not the same claim, and legacy processing has generally optimized for the first at the expense of the second — for the specific class of larger signaling peptides, roughly in the range of a few thousand to around a hundred thousand daltons, that depend on tertiary and quaternary structure to function at all. Below that range, peptides are typically too small to hold a stable fold in the first place. Above it, they tend to be recognized as foreign by the immune system regardless of processing method. It's the band in between — where structure is both possible and fragile — that legacy heat-based methods put most at risk.
The engineering problem, reframed
If heat is what destroys the signal, the obvious question is why the industry doesn't just process at lower temperatures. The honest answer is that lower temperatures are slower, and slower conflicts with industrial throughput — so processors have generally treated the tradeoff as fixed rather than worth engineering around. We think that tradeoff is not fixed; it's a design choice, and one that current sourcing standards make easier to revisit than it used to be. Specific-pathogen-free sourcing reduces the bioburden a process has to guard against in the first place, which changes how much thermal or chemical force is actually necessary to reach an acceptable safety margin — as opposed to how much has simply been standard practice.
That's the engineering problem our processing work is aimed at: preserving native structure through isolation, using controlled, lower-temperature methods paired with non-thermal approaches to pathogen safety, rather than defaulting to heat as the only lever available. We're not there because it's easy. We're there because the alternative — heat-sterilized but functionally silent material — isn't actually solving the problem legacy manufacturing set out to solve.